Abbott Laboratories (ABT)

Name: Abbott Laboratories (ABT): results, filings decoded, planned insider sales, 13F holders, insiders, Congress and short interest
Creator: GreekSoup
License: https://creativecommons.org/licenses/by/4.0/

Compare with another name

Abbott Laboratories (ABT) reported revenue of $11.2 billion for Q1 FY2026, the quarter ended 31 March 2026, up 7.8% on the same quarter a year earlier. Net income was $1.1 billion, down 18.7% on the year, and diluted earnings per share $0.61. The figures are the company's own, from the 10-Q it filed with the SEC on 29 April 2026.

Revenue$11.2 billionup 7.8%

Net income$1.1 billiondown 18.7%

Diluted EPS$0.61

QuarterQ1 FY2026ended 31 March 2026

Ratios

From the filings

ROE12.1%

ROCE9.4%

Operating margin17.1%

Net margin13.9%

FCF margin16.3%

Interest cover14.38

Debt to equity0.57

Cash conversion1.51

Share count, 1 year0.1%

Sales CAGR, 3 years0.5%

Profit CAGR, 3 years-2.0%

EPS, TTM$3.57

At the close of 21 September 2026

Price$102.98

Market cap$179.4 billion

Stock P/E28.85

Price to book3.45

EV / EBITDA18.61

Dividend yield2.3%

Market cap / sales3.97

52-week high$136.62

52-week low$82.56

Price, 1 year-24.3%

Price CAGR, 3 years1.6%

Price CAGR, 5 years-3.7%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on long-term debt as Abbott Laboratories files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Show

50-day average 200-day average Volume

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on ABT

Filings	26 in twelve months: 14 current reports (8-K), about 4 other events; 4 results of operations; 3 charter or bylaw amendment, or fiscal year change; 3 material agreement; 2 regulation fd disclosure
Planned insider sales	12 Form 144 notices in twelve months, $50.9 million; latest 2 September 2026
Options tape	put/call 0.53 by open interest on 23 September 2026; the straddle prices a 2.1% move to 25 September 2026
Holders	14 of the followed funds hold it; largest Geode Capital Management; 3 Schedule 13D or 13G filings in twelve months
Insider trading	11 sales and 6 purchases on Form 4 in twelve months
Congress	12 House trades disclosed in six months
Short interest	22.1 million shares short, 2.67 days to cover at 31 August 2026
Documents	the 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Quarterly results, the last 12 quarters

	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026
Revenue	9,978	10,143	10,241	9,964	10,377	10,635	10,974	10,358	11,142	11,369	11,459	11,164
Cost of revenue	4,483	4,605	4,556	4,463	4,603	4,698	4,942	4,468	4,854	5,075	4,922	4,890
Gross profit	5,495	5,538	5,685	5,501	5,774	5,937	6,032	5,890	6,288	6,294	6,537	6,274
Gross margin	55%	55%	56%	55%	56%	56%	55%	57%	56%	55%	57%	56%
R&D	715	672	700	684	698	713	749	716	725	766	735	767
SG&A	2,740	2,723	2,724	2,959	2,936	2,895	2,907	3,061	3,091	3,051	3,129	3,740
Operating income	1,542	1,647	1,780	1,386	1,669	1,859	1,911	1,693	2,052	2,057	2,251	1,345
Operating margin	15%	16%	17%	14%	16%	17%	17%	16%	18%	18%	20%	12%
Interest expense	159	166	159	141	140	142	136	131	121	121	120	174
Pre-tax income	1,636	1,671	1,795	1,436	1,607	1,940	2,030	1,778	2,150	2,180	2,358	1,449
Tax rate	16%	14%	11%	15%	19%	15%	-355%	25%	17%	25%	25%	26%
Net income	1,375	1,436	1,594	1,225	1,302	1,646	9,229	1,325	1,779	1,644	1,776	1,077
Net margin	14%	14%	16%	12%	13%	15%	84%	13%	16%	14%	15%	10%
Diluted EPS	$0.78	$0.82	$0.91	$0.70	$0.74	$0.94	$5.26	$0.76	$1.01	$0.94	$1.01	$0.61
Operating cash flow	1,203	1,877	3,038	1,025	1,960	2,705	2,868	1,417	2,047	2,787	3,315	1,315
Capital expenditure	507	560	755	398	533	556	720	484	502	496	689	399
Free cash flow	696	1,317	2,283	627	1,427	2,149	2,148	933	1,545	2,291	2,626	916
Buybacks	426	2.0	259	226	3.0	751	315	280	6.0	305	302	180
Dividends paid	890	888	888	957	961	960	958	1,026	1,029	1,031	1,030	1,098
Shares outstanding	1,735m	1,736m	1,735m	1,740m	1,740m	1,734m	1,734m	1,740m	1,740m	1,739m	1,738m	1,742m
Filing	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

	FY2014 †	FY2015	FY2016 †	FY2017 †	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	TTM
Revenue	20,247	20,405	20,853	27,390	30,578	31,904	34,608	43,075	43,653	40,109	41,950	44,328	45,134
Cost of revenue	9,218	8,747	9,094	12,409	12,706	13,231	15,003	18,537	19,142	17,975	18,706	19,319	19,741
Gross profit	11,029	11,658	11,759	14,981	17,872	18,673	19,605	24,538	24,511	22,134	23,244	25,009	25,393
Gross margin	54.5%	57.1%	56.4%	54.7%	58.4%	58.5%	56.6%	57.0%	56.1%	55.2%	55.4%	56.4%	56.3%
Research and development	1,345	1,405	1,447	2,260	2,300	2,440	2,420	2,742	2,888	2,741	2,844	2,942	2,993
Selling, general and administrative	6,530	6,785	6,736	9,182	9,744	9,765	9,696	11,324	11,248	10,949	11,697	12,332	13,011
Operating income	2,599	2,867	3,026	1,564	3,650	4,532	5,357	8,425	8,362	6,478	6,825	8,053	7,705
Operating margin	12.8%	14.1%	14.5%	5.7%	11.9%	14.2%	15.5%	19.6%	19.2%	16.2%	16.3%	18.2%	17.1%
Interest expense	150	163	431	904	826	670	546	533	558	637	559	493	536
Pre-tax income	2,518	3,183	1,413	2,231	2,873	4,077	4,968	8,211	8,306	6,664	7,013	8,466	8,137
Income tax	797	577	350	1,878	539	390	497	1,140	1,373	941	-6,389	1,942	1,861
Effective tax rate	31.7%	18.1%	24.8%	84.2%	18.8%	9.6%	10.0%	13.9%	16.5%	14.1%	-91.1%	22.9%	22.9%
Net income	2,284	4,423	1,400	477	2,368	3,687	4,495	7,071	6,933	5,723	13,402	6,524	6,276
Net margin	11.3%	21.7%	6.7%	1.7%	7.7%	11.6%	13.0%	16.4%	15.9%	14.3%	31.9%	14.7%	13.9%
Diluted EPS	$1.49	$2.92	$0.94	$0.27	$1.33	$2.06	$2.50	$3.94	$3.91	$3.26	$7.64	$3.72	$3.57
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

	FY2014 †	FY2015	FY2016 †	FY2017 †	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	TTM
Operating cash flow	3,675	2,966	3,203	5,570	6,300	6,136	7,901	10,533	9,581	7,261	8,558	9,566	9,464
Capital expenditure	1,077	1,110	1,121	1,135	1,394	1,638	2,177	1,885	1,777	2,202	2,207	2,171	2,086
Free cash flow	2,598	1,856	2,082	4,435	4,906	4,498	5,724	8,648	7,804	5,059	6,351	7,395	7,378
Free cash flow margin	12.8%	9.1%	10.0%	16.2%	16.0%	14.1%	16.5%	20.1%	17.9%	12.6%	15.1%	16.7%	16.3%
Depreciation and amortisation	1,548	1,472	1,353	3,021	3,278	3,014	3,327	3,538	3,267	3,243	3,218	3,116	3,163
Share-based compensation	246	292	310	406	477	519	546	640	685	644	673	664	692
Buybacks	2,195	2,237	522	117	238	718	403	2,299	3,795	1,227	1,295	893	793
Dividends paid	1,342	1,443	1,539	1,849	1,974	2,270	2,560	3,202	3,309	3,556	3,836	4,116	4,188
Dividend per share	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$1.92	$2.08	$2.24	$2.40	n/a
Diluted shares, weighted	1,527m	1,506m	1,483m	1,749m	1,770m	1,781m	1,786m	1,789m	1,764m	1,749m	1,748m	1,748m	1,747m
Shares outstanding at period end	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	1,742m
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

	FY2014 †	FY2015	FY2016 †	FY2017 †	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	TTM
Total assets	41,275	41,247	52,666	76,250	67,173	67,887	72,548	75,196	74,438	73,214	81,414	86,713	110,429
Cash and equivalents	4,063	5,001	18,620	9,407	3,844	3,860	6,838	9,799	9,882	6,896	7,616	8,522	6,803
Receivables	3,586	3,418	3,248	5,249	5,182	5,425	6,414	6,487	6,218	6,565	6,925	7,929	8,210
Inventory	2,643	2,599	2,434	3,601	3,796	4,316	5,012	5,157	6,173	6,570	6,194	6,488	6,989
Goodwill	10,067	9,638	7,683	24,020	23,254	23,195	23,744	23,231	22,799	23,679	23,108	24,035	35,221
Long-term debt	3,448	5,874	20,684	27,718	19,366	17,938	18,534	18,050	16,773	14,679	14,125	12,929	29,638
Operating lease liabilities	n/a	n/a	n/a	n/a	n/a	755	902	956	943	949	896	931	n/a
Shareholders' equity	21,526	21,211	20,538	30,897	30,524	31,088	32,784	35,802	36,686	38,603	47,664	52,130	52,061
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

	10 years	5 years	3 years	TTM
Sales growth, compounded	8.1%	5.1%	0.5%	6.6%
Profit growth, compounded	4.0%	7.7%	-2.0%	-53.5%
Return on equity, average	13.6%	18.8%	18.5%	12.5%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Pharmaceutical Preparations

Company	Market cap	P/E	ROE	Op. margin	Sales growth TTM	Debt to equity	Div. yield
Eli Lilly & Co. LLY	$1.10 trillion	39.09	78.8%	n/a	49.6%	1.41	0.5%
Johnson & Johnson JNJ	$649.4 billion	31.30	24.8%	n/a	8.1%	0.44	1.9%
ABBVIE Inc. ABBV	$467.4 billion	74.71	n/a	26.2%	10.4%	n/a	2.6%
Merck & Co., Inc. MRK	$368.8 billion	119.60	7.6%	n/a	4.6%	1.29	2.2%
Abbott Laboratories ABT	$179.4 billion	28.85	12.1%	17.1%	6.6%	0.57	2.3%
Pfizer Inc. PFE	$158.1 billion	36.50	5.1%	n/a	-0.2%	0.71	6.2%
Vertex Pharmaceuticals Inc. / MA VRTX	$129.4 billion	29.74	21.8%	38.0%	10.2%	0.00	n/a
Bristol-Myers Squibb Co. BMY	$127.9 billion	13.76	41.6%	24.2%	3.1%	1.92	4.0%
Regeneron Pharmaceuticals, Inc. REGN	$84.6 billion	19.77	13.7%	24.7%	9.3%	0.06	0.5%
Zoetis Inc. ZTS	$29.5 billion	11.75	83.1%	n/a	1.4%	2.87	2.8%
Viatris Inc. VTRS	$19.6 billion	n/a	-2.9%	-0.6%	4.4%	0.81	2.8%

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

Filing	Period	Filed	Where
10-Q	30 June 2026	28 July 2026	EDGAR
10-Q	31 March 2026	29 April 2026	EDGAR
10-K	31 December 2025	20 February 2026	EDGAR
10-Q	30 September 2025	29 October 2025	EDGAR
10-Q	30 June 2025	30 July 2025	EDGAR
10-Q	31 March 2025	30 April 2025	EDGAR
10-K	31 December 2024	21 February 2025	EDGAR
10-Q	30 September 2024	31 October 2024	EDGAR
10-Q	30 June 2024	31 July 2024	EDGAR
10-Q	31 March 2024	2 May 2024	EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install